FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023463042> ?p ?o ?g. }

• W2023463042 endingPage "39469" @default.
• W2023463042 startingPage "39461" @default.
• W2023463042 abstract "We have previously demonstrated the anti-tumor activity of nitrosylcobalamin (NO-Cbl), an analog of vitamin B12 that delivers nitric oxide (NO) and increases the expression of tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) and its receptors in human tumors. The specific aim of this study was to examine whether NO-Cbl could sensitize drug-resistant melanomas to Apo2L/TRAIL. Antiproliferative effects of NO-Cbl and Apo2L/TRAIL were assessed in malignant melanomas and non-tumorigenic melanocyte and fibroblast cell lines. Athymic nude mice bearing human melanoma A375 xenografts were treated with NO-Cbl and Apo2L/TRAIL. Apoptosis was measured by TUNEL and confirmed by examining levels and activity of key mediators of apoptosis. The activation status of NF-kappa B was established by assaying DNA binding, luciferase reporter activity, the phosphorylation status of I kappa B alpha, and in vitro IKK activity. NO-Cbl sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by Apo2L/TRAIL but had minimal effect on normal cell lines. NO-Cbl and Apo2L/TRAIL exerted synergistic anti-tumor activity against A375 xenografts. Treatment with NO-Cbl followed by Apo2L/TRAIL induced apoptosis in Apo2L/TRAIL-resistant tumor cells, characterized by cleavage of caspase-3, caspase-8, and PARP. NO-Cbl inhibited IKK activation, characterized by decreased phosphorylation of I kappa B alpha and inhibition of NF-kappa B DNA binding activity. NO-Cbl suppressed Apo2L/TRAIL- and TNF-alpha-mediated activation of a transfected NF-kappa B-driven luciferase reporter. XIAP, an inhibitor of apoptosis, was inactivated by NO-Cbl. NO-Cbl treatment rendered Apo2L/TRAIL-resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo. The use of NO-Cbl and Apo2L/TRAIL capitalizes on the tumor-specific properties of both agents and represents a promising anti-cancer combination." @default.
• W2023463042 created "2016-06-24" @default.
• W2023463042 creator A5007835252 @default.
• W2023463042 creator A5011842741 @default.
• W2023463042 creator A5020048938 @default.
• W2023463042 creator A5024356456 @default.
• W2023463042 creator A5040132550 @default.
• W2023463042 creator A5056562780 @default.
• W2023463042 creator A5065048691 @default.
• W2023463042 creator A5066313762 @default.
• W2023463042 creator A5083441292 @default.
• W2023463042 creator A5090436641 @default.
• W2023463042 date "2003-10-01" @default.
• W2023463042 modified "2023-10-09" @default.
• W2023463042 title "Suppression of NF-κB Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL" @default.
• W2023463042 cites W1484817497 @default.
• W2023463042 cites W187385584 @default.
• W2023463042 cites W1967742670 @default.
• W2023463042 cites W1978480779 @default.
• W2023463042 cites W1978879532 @default.
• W2023463042 cites W1979520552 @default.
• W2023463042 cites W1982658621 @default.
• W2023463042 cites W1985892848 @default.
• W2023463042 cites W1996267589 @default.
• W2023463042 cites W1998507456 @default.
• W2023463042 cites W2001931708 @default.
• W2023463042 cites W2002408013 @default.
• W2023463042 cites W2007062088 @default.
• W2023463042 cites W2010956089 @default.
• W2023463042 cites W2019465386 @default.
• W2023463042 cites W2024240555 @default.
• W2023463042 cites W2029463606 @default.
• W2023463042 cites W2038118195 @default.
• W2023463042 cites W2038408855 @default.
• W2023463042 cites W2052703537 @default.
• W2023463042 cites W2056217426 @default.
• W2023463042 cites W2059126161 @default.
• W2023463042 cites W2061876552 @default.
• W2023463042 cites W2075381893 @default.
• W2023463042 cites W2077945404 @default.
• W2023463042 cites W2089684638 @default.
• W2023463042 cites W2092508425 @default.
• W2023463042 cites W2094985040 @default.
• W2023463042 cites W2096505980 @default.
• W2023463042 cites W2102723961 @default.
• W2023463042 cites W2106284224 @default.
• W2023463042 cites W2109689528 @default.
• W2023463042 cites W2115732428 @default.
• W2023463042 cites W2119326933 @default.
• W2023463042 cites W2130407652 @default.
• W2023463042 cites W2130988210 @default.
• W2023463042 cites W2132595661 @default.
• W2023463042 cites W2133499457 @default.
• W2023463042 cites W2134668672 @default.
• W2023463042 cites W2138668131 @default.
• W2023463042 cites W2144109738 @default.
• W2023463042 cites W2145356695 @default.
• W2023463042 cites W2150033965 @default.
• W2023463042 cites W2169053713 @default.
• W2023463042 cites W2290622880 @default.
• W2023463042 cites W2329105219 @default.
• W2023463042 cites W2330988907 @default.
• W2023463042 cites W2409672023 @default.
• W2023463042 cites W2411875378 @default.
• W2023463042 cites W36502835 @default.
• W2023463042 cites W4313335805 @default.
• W2023463042 doi "https://doi.org/10.1074/jbc.m306111200" @default.
• W2023463042 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6885610" @default.
• W2023463042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31784479" @default.
• W2023463042 hasPublicationYear "2003" @default.
• W2023463042 type Work @default.
• W2023463042 sameAs 2023463042 @default.
• W2023463042 citedByCount "76" @default.
• W2023463042 countsByYear W20234630422012 @default.
• W2023463042 countsByYear W20234630422013 @default.
• W2023463042 countsByYear W20234630422014 @default.
• W2023463042 countsByYear W20234630422015 @default.
• W2023463042 countsByYear W20234630422017 @default.
• W2023463042 countsByYear W20234630422018 @default.
• W2023463042 countsByYear W20234630422021 @default.
• W2023463042 countsByYear W20234630422022 @default.
• W2023463042 crossrefType "journal-article" @default.
• W2023463042 hasAuthorship W2023463042A5007835252 @default.
• W2023463042 hasAuthorship W2023463042A5011842741 @default.
• W2023463042 hasAuthorship W2023463042A5020048938 @default.
• W2023463042 hasAuthorship W2023463042A5024356456 @default.
• W2023463042 hasAuthorship W2023463042A5040132550 @default.
• W2023463042 hasAuthorship W2023463042A5056562780 @default.
• W2023463042 hasAuthorship W2023463042A5065048691 @default.
• W2023463042 hasAuthorship W2023463042A5066313762 @default.
• W2023463042 hasAuthorship W2023463042A5083441292 @default.
• W2023463042 hasAuthorship W2023463042A5090436641 @default.
• W2023463042 hasBestOaLocation W20234630421 @default.
• W2023463042 hasConcept C153911025 @default.
• W2023463042 hasConcept C17991360 @default.
• W2023463042 hasConcept C185592680 @default.
• W2023463042 hasConcept C190283241 @default.
• W2023463042 hasConcept C196795494 @default.

• next